Cargando…
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
OBJECTIVE: We aimed at comparing clinical/immunological outcomes in human immunodeficiency virus (HIV)-infected patients who were treated with CYP2B6-guided and conventional efavirenz (EFV) therapy. METHODS: This study was a 24-week prospective randomized controlled trial. Eligible patients were HIV...
Autores principales: | Damronglerd, Pansachee, Sukasem, Chonlaphat, Thipmontree, Wilawan, Puangpetch, Apichaya, Kiertiburanakul, Sasisopin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638311/ https://www.ncbi.nlm.nih.gov/pubmed/26622191 http://dx.doi.org/10.2147/PGPM.S86446 |
Ejemplares similares
-
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
por: Bushyakanist, Asalaysa, et al.
Publicado: (2015) -
Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
por: Chamnanphon, Monpat, et al.
Publicado: (2021) -
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study
por: Wongprikorn, Asita, et al.
Publicado: (2016) -
Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
por: Chuwongwattana, Sumonrat, et al.
Publicado: (2020) -
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
por: Sukasem, Chonlaphat, et al.
Publicado: (2013)